Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Haemonetics Receives Favorable Ruling In Patent Lawsuit Against Competitive Technology
On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December
On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December
Synthetech has announced financial results for its fiscal fourth quarter and fiscal year, which ended March 31, 2009. For the fourth quarter ended March 31, 2009, revenue was
A patent appeals board had ruled in favor of Affymetrix, as did the U.S. District Court for the Northern District of California. But the U.S. Court of Appeals
Johnson & Johnson has announced the results of ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207. The drug will be used for the treatment of
CombinatoRx has declared positive results from a Phase-I clinical study, evaluating the relative bioavailability of an oral once-daily aligned-release (AR) formulation of Synavive. The pharmacokinetic profiles observed in
Dave has continually proven his leadership ability by developing and implementing initiatives that increase our operational efficiencies, allowing us during this recessionary period to control costs and conserve
Peregrine has highlighted the progress it has achieved in its Phase II program, assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a
Advaxis has received the FDA letter denying the company’s request for Orphan Drug Designation (ODD) for the use of Adxs11-001 in invasive cervix cancer. FDA stated that their
EyeGate has announced that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, has improved signs and symptoms in patients with dry eye syndrome (DES).
PDI, a provider of sales and marketing support to US pharmaceutical companies, and The Medical Affairs Company, provider of customized medical science laison and medical affairs services, have